Literature DB >> 9301998

Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.

J P Gangneux1, A Sulahian, Y J Garin, F Derouin.   

Abstract

BALB/c mice with an experimental visceral leishmaniasis produced by Leishmania infantum were treated with aminosidine sulphate alone or combined with meglumine antimoniate. Parasite burdens in the liver and spleen were determined by subculturings using a sensitive microtitration method. Treatments with aminosidine alone decreased the parasite burdens compared with those observed in the untreated mice, but were less efficacious than meglumine antimoniate. Aminosidine combined with meglumine antimoniate resulted in an increased efficacy compared with either drug given alone. However, these regimens were associated with toxicities and with persistence of hepatic and splenic leishmanial foci after drug administrations.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301998     DOI: 10.1093/jac/40.2.287

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

1.  Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum.

Authors:  J P Gangneux; M Dullin; A Sulahian; Y J Garin; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs.

Authors:  Nishi Shakya; Preeti Bajpai; Suman Gupta
Journal:  J Parasit Dis       Date:  2011-05-20

3.  Combination therapy with paromomycin-associated stearylamine-bearing liposomes cures experimental visceral leishmaniasis through Th1-biased immunomodulation.

Authors:  Antara Banerjee; Manjarika De; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

4.  Real-time PCR as a new tool for quantifying Leishmania infantum in liver in infected mice.

Authors:  S Bretagne; R Durand; M Olivi; J F Garin; A Sulahian; D Rivollet; M Vidaud; M Deniau
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

5.  Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis.

Authors:  Rafael Balaña-Fouce; Christopher F Prada; José María Requena; Mark Cushman; Yves Pommier; Raquel Álvarez-Velilla; José Miguel Escudero-Martínez; Estefania Calvo-Álvarez; Yolanda Pérez-Pertejo; Rosa M Reguera
Journal:  Antimicrob Agents Chemother       Date:  2012-07-30       Impact factor: 5.191

Review 6.  Trypanosomatids topoisomerase re-visited. New structural findings and role in drug discovery.

Authors:  Rafael Balaña-Fouce; Raquel Alvarez-Velilla; Christopher Fernández-Prada; Carlos García-Estrada; Rosa M Reguera
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-08-24       Impact factor: 4.077

7.  The combination therapy of meglumine antimoniate and oxiranes (epoxy-α-lapachone and epoxymethyl-lawsone) enhance the leishmanicidal effect in mice infected by Leishmania (Leishmania) amazonensis.

Authors:  Luiz Filipe Gonçalves-Oliveira; Franklin Souza-Silva; Luzia Monteiro de Castro Côrtes; Laura Barral Veloso; Bernardo Acácio Santini Pereira; Lea Cysne-Finkelstein; Guilherme Curty Lechuga; Saulo Cabral Bourguignon; Fernando Almeida-Souza; Kátia da Silva Calabrese; Vitor Francisco Ferreira; Carlos Roberto Alves
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-08-12       Impact factor: 4.077

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.